Literature DB >> 22840745

Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Diana F Silva1, J Eva Selfridge, Jianghua Lu, Lezi E, Sandra M Cardoso, Russell H Swerdlow.   

Abstract

Mitochondria from persons with Alzheimer's disease (AD) differ from those of age-matched control subjects. Differences in mitochondrial morphology and function are well documented, and are not brain-limited. Some of these differences are present during all stages of AD, and are even seen in individuals who are without AD symptoms and signs but who have an increased risk of developing AD. This chapter considers the status of mitochondria in AD subjects, the potential basis for AD subject mitochondrial perturbations, and the implications of these perturbations. Data from multiple lines of investigation, including epidemiologic, biochemical, molecular, and cytoplasmic hybrid studies, are reviewed. The possibility that mitochondria could potentially constitute a reasonable AD therapeutic target is discussed, as are several potential mitochondrial medicine treatment strategies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840745      PMCID: PMC3625400          DOI: 10.1016/B978-0-12-394816-8.00003-9

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  288 in total

Review 1.  Caspase-mediated degeneration in Alzheimer's disease.

Authors:  David H Cribbs; Wayne W Poon; Robert A Rissman; Mathew Blurton-Jones
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead.

Authors:  Domenico Praticò
Journal:  Neurobiol Aging       Date:  2005-05       Impact factor: 4.673

4.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

Review 5.  Brain aging, Alzheimer's disease, and mitochondria.

Authors:  Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-09-02

6.  Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.

Authors:  Anat Idan-Feldman; Yulie Schirer; Eleni Polyzoidou; Olga Touloumi; Roza Lagoudaki; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Neurobiol Dis       Date:  2011-07-27       Impact factor: 5.996

7.  Inactivation and reactivation of the mitochondrial α-ketoglutarate dehydrogenase complex.

Authors:  Qingli Shi; Hui Xu; Haiqiang Yu; Nawei Zhang; Yaozu Ye; Alvaro G Estevez; Haiteng Deng; Gary E Gibson
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

8.  Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies.

Authors:  M Broe; C E Shepherd; E A Milward; G M Halliday
Journal:  Acta Neuropathol       Date:  2001-06       Impact factor: 17.088

9.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

10.  Cytochrome c oxidase is decreased in Alzheimer's disease platelets.

Authors:  Sandra Morais Cardoso; M Teresa Proença; Sancha Santos; Isabel Santana; Catarina R Oliveira
Journal:  Neurobiol Aging       Date:  2004-01       Impact factor: 4.673

View more
  30 in total

1.  SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.

Authors:  Alfredo Ramirez; Wiesje M van der Flier; Christine Herold; David Ramonet; Stefanie Heilmann; Piotr Lewczuk; Julius Popp; André Lacour; Dmitriy Drichel; Eva Louwersheimer; Markus P Kummer; Carlos Cruchaga; Per Hoffmann; Charlotte Teunissen; Henne Holstege; Johannes Kornhuber; Oliver Peters; Adam C Naj; Vincent Chouraki; Céline Bellenguez; Amy Gerrish; Reiner Heun; Lutz Frölich; Michael Hüll; Lara Buscemi; Stefan Herms; Heike Kölsch; Philip Scheltens; Monique M Breteler; Eckart Rüther; Jens Wiltfang; Alison Goate; Frank Jessen; Wolfgang Maier; Michael T Heneka; Tim Becker; Markus M Nöthen
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

2.  Declining Skeletal Muscle Mitochondrial Function Associated With Increased Risk of Depression in Later Life.

Authors:  Patrick J Brown; Nicholas Brennan; Adam Ciarleglio; Chen Chen; Carolina Montes Garcia; Stephanie Gomez; Steven P Roose; Bret R Rutherford; Eleanor M Simonsick; Richard G Spencer; Luigi Ferrucci
Journal:  Am J Geriatr Psychiatry       Date:  2019-04-06       Impact factor: 4.105

3.  The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo.

Authors:  Shira Simonovitch; Eran Schmukler; Eliezer Masliah; Ronit Pinkas-Kramarski; Daniel M Michaelson
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.

Authors:  Ramesh Kandimalla; Maria Manczak; David Fry; Yeguvapalli Suneetha; Hiromi Sesaki; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

5.  Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease.

Authors:  P Hemachandra Reddy; Maria Manczak; Ramesh Kandimalla
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

6.  Impact of C24:0 on actin-microtubule interaction in human neuronal SK-N-BE cells: evaluation by FRET confocal spectral imaging microscopy after dual staining with rhodamine-phalloidin and tubulin tracker green.

Authors:  Amira Zarrouk; Thomas Nury; Aurélien Dauphin; Perrine Frère; Jean-Marc Riedinger; Claude-Marie Bachelet; Frédérique Frouin; Thibault Moreau; Mohamed Hammami; Edmond Kahn; Gérard Lizard
Journal:  Funct Neurol       Date:  2015 Jan-Mar

7.  Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.

Authors:  Maria Manczak; Ramesh Kandimalla; David Fry; Hiromi Sesaki; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

8.  Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes.

Authors:  Way Seah Lee; Ronald J Sokol
Journal:  J Pediatr       Date:  2013-06-28       Impact factor: 4.406

9.  Comparing amyloid-β deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys.

Authors:  Hideo Tsukada; Shingo Nishiyama; Hiroyuki Ohba; Masakatsu Kanazawa; Takeharu Kakiuchi; Norihiro Harada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-12       Impact factor: 9.236

Review 10.  Oxidative stress in Alzheimer's disease.

Authors:  Zhichun Chen; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2014-03-24       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.